APTOSE BIOSCIENCES INC (APTO) Fundamental Analysis & Valuation
NASDAQ:APTO • CA03835T4081
Current stock price
1.71 USD
-1.44 (-45.71%)
At close:
2.16 USD
+0.45 (+26.32%)
After Hours:
This APTO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. APTO Profitability Analysis
1.1 Basic Checks
- In the past year APTO has reported negative net income.
- In the past year APTO has reported a negative cash flow from operations.
- In the past 5 years APTO always reported negative net income.
- APTO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -327.57%, APTO is doing worse than 95.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -327.57% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- APTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. APTO Health Analysis
2.1 Basic Checks
- There is no outstanding debt for APTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -79.84, we must say that APTO is in the distress zone and has some risk of bankruptcy.
- APTO has a worse Altman-Z score (-79.84) than 95.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -79.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.05 indicates that APTO should not have too much problems paying its short term obligations.
- APTO's Current ratio of 1.05 is on the low side compared to the rest of the industry. APTO is outperformed by 87.89% of its industry peers.
- A Quick Ratio of 1.05 indicates that APTO should not have too much problems paying its short term obligations.
- APTO's Quick ratio of 1.05 is on the low side compared to the rest of the industry. APTO is outperformed by 86.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 1.05 |
3. APTO Growth Analysis
3.1 Past
- APTO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.66%.
EPS 1Y (TTM)-237.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- APTO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.16% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.43%
EPS Next 2Y38.98%
EPS Next 3Y26.36%
EPS Next 5Y17.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. APTO Valuation Analysis
4.1 Price/Earnings Ratio
- APTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year APTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as APTO's earnings are expected to grow with 26.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.98%
EPS Next 3Y26.36%
5. APTO Dividend Analysis
5.1 Amount
- No dividends for APTO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APTO Fundamentals: All Metrics, Ratios and Statistics
1.71
-1.44 (-45.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners6.66%
Inst Owner Change0%
Ins Owners1.13%
Ins Owner Change0%
Market Cap4.36M
Revenue(TTM)N/A
Net Income(TTM)-35.80M
Analysts82.5
Price Target85.85 (4920.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.9%
Min EPS beat(2)64.27%
Max EPS beat(2)69.52%
EPS beat(4)4
Avg EPS beat(4)37.14%
Min EPS beat(4)3.29%
Max EPS beat(4)69.52%
EPS beat(8)6
Avg EPS beat(8)16.25%
EPS beat(12)9
Avg EPS beat(12)9.71%
EPS beat(16)12
Avg EPS beat(16)10.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.86%
PT rev (3m)2004.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-767.77%
EPS NY rev (1m)-2900%
EPS NY rev (3m)-1657.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-26.07
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-14.58
FCFYN/A
OCF(TTM)-14.58
OCFYN/A
SpS0
BVpS-3.58
TBVpS-3.58
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -327.57% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | -79.84 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.76%
Cap/Depr(5y)62.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-237.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.15%
EPS Next Y91.43%
EPS Next 2Y38.98%
EPS Next 3Y26.36%
EPS Next 5Y17.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.1%
EBIT Next 3Y11.61%
EBIT Next 5YN/A
FCF growth 1Y6.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.39%
OCF growth 3YN/A
OCF growth 5YN/A
APTOSE BIOSCIENCES INC / APTO Fundamental Analysis FAQ
What is the ChartMill fundamental rating of APTOSE BIOSCIENCES INC (APTO) stock?
ChartMill assigns a fundamental rating of 1 / 10 to APTO.
Can you provide the valuation status for APTOSE BIOSCIENCES INC?
ChartMill assigns a valuation rating of 1 / 10 to APTOSE BIOSCIENCES INC (APTO). This can be considered as Overvalued.
What is the profitability of APTO stock?
APTOSE BIOSCIENCES INC (APTO) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for APTO stock?
The Earnings per Share (EPS) of APTOSE BIOSCIENCES INC (APTO) is expected to grow by 91.43% in the next year.